Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 1999

View Archived Issues

SkyePharma makes solid progress during first half of 1999

Pivotal trial of Remune begins

DuPont and Pharmasset establish collaboration for development of antiviral compounds

BioTransplant achieves milestone in xenotransplantation collaboration with Novartis

Positive results received from interim analysis of Crinone treatment

Cell Genesys enters cancer gene therapy collaboration with Rigel

Corvas granted SBIR award for malaria research

Shire and Janssen seek approval for galantamine in the U.S.

Gliatech completes phase I study of Perceptin

PDL and SB establish asthma therapy collaboration

Licensing opportunity from NIH: chicoric acid analogues as inhibitors of HIV-1 integrase

Orally active antimalarial compound acts via a newly identified therapeutic target

Tamiflu, first oral influenza neuraminidase inhibitor, launched today in Switzerland

Sildenafil in pulmonary hypertension and heart failure

Antiischemic NHE-1 inhibitors synthesized at Pfizer

New HMR compounds inhibit both neuronal apoptosis and cell cycle progression

Alpha1A/1L-adrenoceptor agonists disclosed for urinary incontinence, etc.

American Cyanamid presents newest MMP inhibitors

Pharma Mar presents phase I findings for ecteinascidin 743 at scientific forum

Dual NEP and ECE inhibitors from Solvay potentially useful in cardiac insufficiency

Continued focus at Neurogen on GABA-A receptor ligands

Preliminary results with AG-7088 in humans presented at ICAAC

Early phase II and other data presented at 39th ICAAC for GW-420867X

HIV protease inhibitor Prozei becomes available today in Japan

Sonus and Nycomed Amersham establish ultrasound contrast agreement

Cancer patients being enrolled at UNC for new trial evaluating third-generation SERM

FDA approves Evista for treatment of postmenopausal osteoporosis